Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 17;12(8):1992.
doi: 10.3390/diagnostics12081992.

Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2

Arzum Erdem  1 , Huseyin Senturk  1 , Esma Yildiz  1 , Meltem Maral  1
Affiliations

Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2

Arzum Erdem et al. Diagnostics (Basel). .

Abstract

After the COVID-19 pandemic started all over the world, great importance was placed on the development of sensitive and selective bioanalytical assays for the rapid detection of the highly pathogenic SARS-CoV-2 virus causing COVID-19 disease. In this present work, an impedimetric immunosensor was developed and applied for rapid, reliable, sensitive and selective detection of the SARS-CoV-2 S1 protein. To detect the SARS-CoV-2 virus, targeting of the spike S1 protein was achieved herein by using S1 protein-specific capture antibody (Cab-S1) immobilized screen-printed electrode (SPE) in combination with the electrochemical impedance spectroscopy (EIS) technique. With the impedimetric immunosensor, the detection limit for S1 protein in buffer medium was found to be 0.23 ng/mL (equal to 23.92 amol in 8 µL sample) in the linear concentration range of S1 protein from 0.5 to 10 ng/mL. In the artificial saliva medium, it was found to be 0.09 ng/mL (equals to 9.36 amol in 8 µL sample) in the linear concentration range of S1 protein between 0.1 and 1 ng/mL. The selectivity of the impedimetric immunosensor toward S1 protein was tested against influenza hemagglutinin antigen (HA) in the buffer medium as well as in artificial saliva.

Keywords: COVID-19; SARS-CoV-2 S1 protein; electrochemical immunosensors; electrochemical impedance spectroscopy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Development of label-free immunosensor with its application for impedimetric detection of spike S1 protein of SARS-CoV-2.
Figure 2
Figure 2
(A) Nyquist diagrams showing the data obtained by impedimetric immunosensor for the detection of S1 protein in its concentrations varying from 0.5 to 10 ng/mL prepared in buffer medium. (B) Calibration curve obtained by impedimetric detection of spike S1 protein of SARS-CoV-2 (n = 6).
Figure 3
Figure 3
Histograms presenting the data obtained in the selectivity study performed in different concentrations of S1 protein or HA. Gray columns represent full procedure in the presence of spike S1 protein, and green-striped columns represent full procedure in the presence of HA (n = 3).
Figure 4
Figure 4
(A) Nyquist diagrams showing the response of the label-free impedimetric immunosensor at increasing concentrations of S1 protein in the range of 0–1 ng/mL prepared in diluted artificial saliva (1:20). (B) Calibration curve presenting the data for the impedimetric determination of spike S1 protein of SARS-CoV-2 in diluted artificial saliva (1:20) (n = 3).
Figure 5
Figure 5
Histograms presenting the data obtained in the selectivity study performed on different concentrations of S1 protein or HA prepared in diluted artificial saliva (1:20). Gray columns represent full procedure in the presence of spike S1 protein, and green-striped columns represent full procedure in the presence of HA (n = 3).
Figure 6
Figure 6
Histograms presenting the data obtained in the selectivity study performed with 1 ng/mL S1 protein, 1 ng/mL HA and the mixture sample containing 1 ng/mL S1 protein and 1 ng/mL HA prepared in diluted artificial saliva (1:20) (n = 3).
See this image and copyright information in PMC

References

    1. Zhu C., He G., Yin Q., Zeng L., Ye X., Shi Y., Xu W. Molecular biology of the SARs-CoV-2 spike protein: A review of current knowledge. J. Med. Virol. 2021;93:5729–5741. doi: 10.1002/jmv.27132. - DOI - PMC - PubMed
    1. Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271–280.e8. doi: 10.1016/j.cell.2020.02.052. - DOI - PMC - PubMed
    1. Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu. Rev. Virol. 2016;3:237–261. doi: 10.1146/annurev-virology-110615-042301. - DOI - PMC - PubMed
    1. Fabiani L., Saroglia M., Galatà G., De Santis R., Fillo S., Luca V., Faggioni G., D’Amore N., Regalbuto E., Salvatori P., et al. Magnetic beads combined with carbon black-based screen-printed electrodes for COVID-19: A reliable and miniaturized electrochemical immunosensor for SARS-CoV-2 detection in saliva. Biosens. Bioelectron. 2021;171:112686. doi: 10.1016/j.bios.2020.112686. - DOI - PMC - PubMed
    1. Li J., Lillehoj P.B. Microfluidic Magneto Immunosensor for Rapid, High Sensitivity Measurements of SARS-CoV-2 Nucleocapsid Protein in Serum. ACS Sens. 2021;6:1270–1278. doi: 10.1021/acssensors.0c02561. - DOI - PMC - PubMed

LinkOut - more resources